Non-small Cell Lung Cancer Metastatic Clinical Trials

141 clinical trials for Non-small Cell Lung Cancer Metastatic across international registries, including 16 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Phase Ib Study of GC101 in NSCLC — RECRUITING · PHASE1
• A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) — RECRUITING · PHASE3
• A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain — RECRUITING · PHASE2
• Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer — RECRUITING · NA
• A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) — RECRUITING · PHASE2
• Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer — RECRUITING
• Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment — RECRUITING · PHASE2
• Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer — RECRUITING · PHASE2
• A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1 — RECRUITING · PHASE1
• Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer — RECRUITING · NA
• PALACE: Cemiplimab Trial According to ctDNA Levels — RECRUITING · PHASE2
• First-line Therapy With Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metatastatic NSCLC (NICReWo Trial) — RECRUITING
• Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients — RECRUITING
• Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations — RECRUITING · PHASE2
• A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib — RECRUITING · PHASE2
• Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer — RECRUITING · PHASE3
• High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis — COMPLETED · PHASE2
• Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease — NOT_YET_RECRUITING · PHASE2
• Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004) — ACTIVE_NOT_RECRUITING · PHASE2
• Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC — TERMINATED · PHASE2
• Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden — NOT_YET_RECRUITING · PHASE3
• ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer — TERMINATED · PHASE2
• HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients — TERMINATED · PHASE3
• Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC — ACTIVE_NOT_RECRUITING · PHASE1
• Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer — ACTIVE_NOT_RECRUITING · NA
• Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Liquid Biopsy Based NGS in Newly Diagnosed NSCLC — ACTIVE_NOT_RECRUITING · NA
• Phase III, Multicenter, Randomized Controlled Clinical Study of Three-Dimensional Radiotherapy for Primary Tumors in Non-Oligometastatic Stage IV Non-Small Cell Lung Cancer — NOT_YET_RECRUITING · NA
• Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma — ACTIVE_NOT_RECRUITING · PHASE4
• An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) — ACTIVE_NOT_RECRUITING · PHASE2
• PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE3
• Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination — ACTIVE_NOT_RECRUITING · PHASE1
• Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M — COMPLETED · PHASE2
• Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung — ACTIVE_NOT_RECRUITING · PHASE2
• A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) — COMPLETED · PHASE2
• A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC — COMPLETED · PHASE2
• Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 — COMPLETED · PHASE1
• Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr — COMPLETED · PHASE3
• Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy — ACTIVE_NOT_RECRUITING · PHASE3
• Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) — COMPLETED · PHASE1
• Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) — ACTIVE_NOT_RECRUITING · PHASE2
• Dacomitinib in Lung Cancer With Uncommon EGFR Mutations — ACTIVE_NOT_RECRUITING · PHASE2
• Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Survival Efficacy of Combined Radiotherapy and Immunotherapy in Patients With Metastatic Non-small Cell Lung Carcinoma — COMPLETED
• A Biomarker Screening Protocol for Participants With Solid Tumors — TERMINATED
• A Study to Investigate LYL797 in Adults With Solid Tumors — TERMINATED · PHASE1
• Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) — TERMINATED · PHASE2
• Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC — COMPLETED · PHASE1

Refine this search